Zentalis Pharmaceuticals (ZNTL) Retained Earnings (2019 - 2026)

Zentalis Pharmaceuticals' Retained Earnings history runs 8 years deep, the most recent figure standing at -$1.2 billion for Q1 2026.

• In Q1 2026, Retained Earnings fell 187.78% year-over-year to -$1.2 billion; the TTM figure through Mar 2026 stood at -$1.2 billion (down 187.78% YoY), while the FY2025 annual figure was $196000.0, up 100.02% from the prior year.
• Retained Earnings for Q1 2026 stood at -$1.2 billion, down from $196000.0 in the prior quarter.
• The five-year high for Retained Earnings was $1.4 billion in Q1 2025, with the low at -$1.2 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$1.4 million (2022), against an average of -$149.3 million.
• The sharpest annual moves came in 2022 and 2024: Retained Earnings surged 1469894.0% in 2022, then tumbled 157901.44% in 2024.
• Zentalis Pharmaceuticals' Retained Earnings stood at -$1.4 million in 2022, then sank by 65573.02% to -$888.6 million in 2023, then dropped by 18.66% to -$1.1 billion in 2024, then soared by 100.02% to $196000.0 in 2025, then tumbled by 626021.94% to -$1.2 billion in 2026.
• Business Quant data shows ZNTL's Retained Earnings at -$1.2 billion in Q1 2026, $196000.0 in Q4 2025, and -$1.2 billion in Q3 2025.